Skip to main content
. Author manuscript; available in PMC: 2011 Nov 4.
Published in final edited form as: Mol Cancer Ther. 2010 Aug 17;9(10):2785–2792. doi: 10.1158/1535-7163.MCT-10-0481

Figure 3.

Figure 3

Effects of the combination of gefitinib and either TAK-701 or PHA-665752 on cell signaling in gefitinib-resistant NSCLC cells. HCC827 cells, HCC827 GR5 cells, or HCC827-HGF2 cells were incubated for 6 h in medium containing 10% serum in the absence or presence of gefitinib (1 μM), PHA-665752 (500 nM), or TAK-701 (50 μg/mL), as indicated. Cell lysates were then prepared and subjected to immunoblot analysis with antibodies to phosphorylated or total forms of EGFR, MET, AKT, or ERK or with those to β-actin.